8月7日，康方生物盘中上涨3.28%，报99.2港元，成交额3.84亿港元。
消息面上，公司海外合作伙伴Summit近日宣布启动依沃西联合维恩妥尤单抗（Nectin-4 ADC）头对头帕博利珠单抗联合维恩妥尤单抗一线治疗局部晚期或转移性尿路上皮癌的国际II/III期注册性临床研究（HARMONi-GU1）。该研究是依沃西第16项注册性/III期临床、第6项国际多中心注册性研究，也是公司IO2.0+ADC2.0战略在泌尿肿瘤领域的关键布局。此外，生物科技板块整体走强，同行业再鼎医药涨15.42%、荣昌生物涨6.48%、百济神州涨2.46%，板块情绪持续活跃。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.